tradingkey.logo

Precipio Inc

PRPO
查看詳細走勢圖
22.190USD
-1.000-4.31%
收盤 12/19, 16:00美東報價延遲15分鐘
38.74M總市值
虧損本益比TTM

Precipio Inc

22.190
-1.000-4.31%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-4.31%

5天

-11.13%

1月

-13.39%

6月

+96.37%

今年開始到現在

+300.56%

1年

+321.06%

查看詳細走勢圖

TradingKey Precipio Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Precipio Inc當前公司基本面數據相對穩定,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名160/208位。機構持股佔比非常高,中期看,股價處於上升通道。近一個月,市場表現較差,但技術面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Precipio Inc評分

相關信息

行業排名
160 / 208
全市場排名
475 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Precipio Inc亮點

亮點風險
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
業績高增長
公司營業收入穩步增長,連續3年增長96.90%
業績增長期
公司處於發展階段,最新年度總收入18.53M美元
估值低估
公司最新PE估值-27.55,處於3年歷史低位
機構加倉
最新機構持股199.00K股,環比增加11.63%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉20.19K股
活躍度降低
近期活躍度降低,過去20天平均換手率0.14

Precipio Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Precipio Inc簡介

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
公司代碼PRPO
公司Precipio Inc
CEODanieli (Ilan S)
網址https://www.precipiodx.com/

常見問題

Precipio Inc(PRPO)的當前股價是多少?

Precipio Inc(PRPO)的當前股價是 22.190。

Precipio Inc 的股票代碼是什麼?

Precipio Inc的股票代碼是PRPO。

Precipio Inc股票的52週最高點是多少?

Precipio Inc股票的52週最高點是28.500。

Precipio Inc股票的52週最低點是多少?

Precipio Inc股票的52週最低點是3.900。

Precipio Inc的市值是多少?

Precipio Inc的市值是38.74M。

Precipio Inc的淨利潤是多少?

Precipio Inc的淨利潤為-4.29M。

現在Precipio Inc(PRPO)的股票是買入、持有還是賣出?

根據分析師評級,Precipio Inc(PRPO)的總體評級為--,目標價格為--。

Precipio Inc(PRPO)股票的每股收益(EPS TTM)是多少

Precipio Inc(PRPO)股票的每股收益(EPS TTM)是-0.806。
KeyAI